<i>Notes from the Field</i>: Surveillance for Multisystem Inflammatory Syndrome in Children — United States, 2023
Anna R Yousaf, Katherine Lindsey, Michael Wu, Ami B. Shah, Rebecca J. Free, Regina M. Simeone, Laura D. Zambrano, Angela P. Campbell, MIS-C Surveillance Authorship Group, S. Crook, Amy Clark, Tiffanie Fulton-Kennedy, Ashley Gent, Walaa M Elbedewy, Gabrielle Williams, Amanda Hartley, Kaleb Kitchens, Gillian Richardson, Marion Deming, Cole Burkholder, Jacob Reece, Tom Haupt, Amanda Mandi, Paige D’Heilly, Ayotola Falodun, C.J. Gil, Chelsea Campbell, Kimberly Carlson, Heather D. Reid, Deepam Thomas, Haytham Safi, Jacqueline Denning, Stacy Davidson, Maya Scullin, Allison Longenberger, Kelly Blythe, Xandy Peterson Pompa, Augustina Manuzak, Spencer Cunningham, Kate Cleavinger, Jannifer Anderson, Carmen B. Rodriguez, Lesley Roush
Abstract
Multisystem inflammatory syndrome in children (MIS-C) is a rare but serious condition typically occurring 2-6 weeks after SARS-CoV-2 infection and characterized by fever and multiorgan involvement (1,2).In May 2020, CDC created an MIS-C case definition and established a passive national surveillance system for voluntary case reporting by state and local health departments.*In 2022, CDC and the Council of State and Territorial Epidemiologists (CSTE) created a new surveillance case definition that went into effect on January 1, 2023 (3).Approximately 87% of cases reported using the 2020 case definition also meet the 2023 case definition.This report describes 2023 MIS-C cases and compares them with cases reported earlier in the COVID-19 pandemic.